Triple
T10401937
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | dabigatran |
E245168
|
entity |
| Predicate | isReversedBy |
P21517
|
FINISHED |
| Object | idarucizumab |
E861730
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: idarucizumab | Statement: [dabigatran, isReversedBy, idarucizumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: idarucizumab Context triple: [dabigatran, isReversedBy, idarucizumab]
-
A.
idarucizumab
chosen
Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
-
B.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
C.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
D.
avelumab
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
-
E.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: isReversedBy Context triple: [dabigatran, isReversedBy, idarucizumab]
-
A.
isInverseOf
chosen
Indicates that one relation reverses the direction of another, so that if the original relates A to B, its inverse relates B to A.
-
B.
reversed
Indicates that the direction or order of a previously defined relationship or sequence between entities is inverted.
-
C.
hasReverse
Indicates that one entity serves as the inverse or opposite counterpart of another entity in a given relationship or operation.
-
D.
followsFrom
Indicates that one fact, event, or state logically or causally results from, is implied by, or comes as a consequence of another.
-
E.
oppositeControlledBy
Indicates that one entity is under the control or influence of another entity that is positioned or defined as its opposite or counterpart.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381be340c8190b05998703d42d224 |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4e9e42da08190a5383df3df6d3c18 |
completed | April 7, 2026, 11:26 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d87e84f7a08190b83ecfec72efb7a7 |
completed | April 10, 2026, 4:37 a.m. |
| PD | Predicate disambiguation | batch_69d4dfb438c481908dff87c47de2f069 |
completed | April 7, 2026, 10:43 a.m. |
Created at: April 6, 2026, 12:08 p.m.